<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kaze AD</submitter><funding>Jackson Heart Study</funding><funding>Jackson State University</funding><funding>University of Mississippi Medical Center</funding><funding>Tougaloo College</funding><funding>National Heart, Lung, and Blood Institute</funding><funding>NHLBI NIH HHS</funding><funding>NIMHD NIH HHS</funding><funding>Mississippi State Department of Health</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><funding>National Institute for Minority Health and Health Disparities</funding><pagination>1163-1170</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9526809</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>34(11)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Little is known on the association of plasma adiponectin with blood pressure (BP) changes in African Americans (AAs). We evaluated the associations between plasma adiponectin and BP progression among AAs.&lt;h4>Methods&lt;/h4>We analyzed data from 1,184 participants without hypertension at baseline (2000-2004) with ≥1 follow-up visits in the Jackson Heart Study. We used robust Poisson regression to generate risk ratios (RRs) for BP progression (an increase by ≥1 BP stage) and incident hypertension.&lt;h4>Results&lt;/h4>Over a median of 7 years, 71% progressed to higher BP stage and 65% developed hypertension. We found evidence of interaction by sex (P-interaction = 0.088). Compared with those in the lowest quartile (Q1), male participants in the highest adiponectin quartile (Q4) had reduced risks of BP progression (RR 0.76 [95% confidence interval, CI, 0.60-0.96]) and incident hypertension (RR 0.74 [95% CI 0.56-0.97]). After accounting for body mass index, this relation persisted among obese men (RR for the highest [vs. lowest] adiponectin quartile: 0.59 [95% CI 0.36-0.97] for incident hypertension, and 0.69 [95% CI 0.45-1.06] for BP progression). Among women, adiponectin was not associated with BP outcomes (RR [95% CI] for Q4 vs. Q1: 1.03 [0.86-1.23] and 1.01 [0.83-1.23] for BP progression and incident hypertension, respectively). Our findings were consistent across both the American College of Cardiology (ACC)/American Heart Association (AHA) and Seventh Joint National Committee (JNC-7) BP categories.&lt;h4>Conclusions&lt;/h4>In a large, community-based sample of AAs, higher adiponectin concentrations were associated with lower risks of BP progression and incident hypertension in men, but no significant association was observed in women.</pubmed_abstract><journal>American journal of hypertension</journal><pubmed_title>Plasma Adiponectin and Blood Pressure Progression in African Americans: The Jackson Heart Study.</pubmed_title><pmcid>PMC9526809</pmcid><funding_grant_id>HHSN268201800015I</funding_grant_id><funding_grant_id>HHSN268201800012I</funding_grant_id><funding_grant_id>HHSN268201800011I</funding_grant_id><funding_grant_id>HHSN268201800014I</funding_grant_id><funding_grant_id>HHSN268201800013I</funding_grant_id><funding_grant_id>K23 HL153774</funding_grant_id><funding_grant_id>HHSN268201800010I</funding_grant_id><pubmed_authors>Bertoni AG</pubmed_authors><pubmed_authors>Echouffo-Tcheugui JB</pubmed_authors><pubmed_authors>Musani SK</pubmed_authors><pubmed_authors>Golden SH</pubmed_authors><pubmed_authors>Correa A</pubmed_authors><pubmed_authors>Kaze AD</pubmed_authors><pubmed_authors>Bidulescu A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Plasma Adiponectin and Blood Pressure Progression in African Americans: The Jackson Heart Study.</name><description>&lt;h4>Background&lt;/h4>Little is known on the association of plasma adiponectin with blood pressure (BP) changes in African Americans (AAs). We evaluated the associations between plasma adiponectin and BP progression among AAs.&lt;h4>Methods&lt;/h4>We analyzed data from 1,184 participants without hypertension at baseline (2000-2004) with ≥1 follow-up visits in the Jackson Heart Study. We used robust Poisson regression to generate risk ratios (RRs) for BP progression (an increase by ≥1 BP stage) and incident hypertension.&lt;h4>Results&lt;/h4>Over a median of 7 years, 71% progressed to higher BP stage and 65% developed hypertension. We found evidence of interaction by sex (P-interaction = 0.088). Compared with those in the lowest quartile (Q1), male participants in the highest adiponectin quartile (Q4) had reduced risks of BP progression (RR 0.76 [95% confidence interval, CI, 0.60-0.96]) and incident hypertension (RR 0.74 [95% CI 0.56-0.97]). After accounting for body mass index, this relation persisted among obese men (RR for the highest [vs. lowest] adiponectin quartile: 0.59 [95% CI 0.36-0.97] for incident hypertension, and 0.69 [95% CI 0.45-1.06] for BP progression). Among women, adiponectin was not associated with BP outcomes (RR [95% CI] for Q4 vs. Q1: 1.03 [0.86-1.23] and 1.01 [0.83-1.23] for BP progression and incident hypertension, respectively). Our findings were consistent across both the American College of Cardiology (ACC)/American Heart Association (AHA) and Seventh Joint National Committee (JNC-7) BP categories.&lt;h4>Conclusions&lt;/h4>In a large, community-based sample of AAs, higher adiponectin concentrations were associated with lower risks of BP progression and incident hypertension in men, but no significant association was observed in women.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Nov</publication><modification>2025-04-21T18:55:39.596Z</modification><creation>2025-04-05T17:25:15.742Z</creation></dates><accession>S-EPMC9526809</accession><cross_references><pubmed>34166486</pubmed><doi>10.1093/ajh/hpab101</doi></cross_references></HashMap>